1. (a) http://www.iacr.fr. (b) http://www.iacr.globocan.fr (c) US National Cancer Institute, Cancer Statistics, https://www.cancer.gov/about-cancer/understanding/statistics (accessed May 31, 2020). (d) R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, CA: Cancer J. Clin., (2020) https://doi.org/10.3322/caac.21590 (e) S. Nekkanti, R. Tokala, N. Shankaraiah, Targeting DNA minor groove by hybrid molecules as anticancer agents, Curr. Med. Chem. 24 (2017) 2887–2907. (f) S. Nagula, S. Nekkanti, O. Ommi, P. S. L. Soukya, Diverse targeted approaches to battle multidrug resistance in cancer, Curr. Med. Chem. 26 (2019) 7059–7080. (g) A. Kamal, S. Nekkanti, N. Shankaraiah, M. Sathish, Future of drug discovery, Drug resistance in bacteria, fungi, malaria and cancer, Springer international publishing, 2017, pp. 609–629.
2. Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches;Hu;J. Med. Chem.,2018
3. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage;Wendorff;J. Mol. Biol.,2012
4. Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes;Wesierska-Gadek;Future Med. Chem.,2012
5. Antitopoisomerase drug action and resistance;Nitiss;Eur. J. Cancer,1996